Patient-derived organoids as a predictive biomarker for treatment response in cancer patients-Reference-Cited by-同舟云学术

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

Published:2021-04-12 Issue:1 Volume:5 Page:
ISSN:2397-768X
Container-title:npj Precision Oncology
language:en
Short-container-title:npj Precis. Onc.

Author:

Wensink G. Emerens^ORCID,Elias Sjoerd G.,Mullenders Jasper,Koopman Miriam,Boj Sylvia F.,Kranenburg Onno W.,Roodhart Jeanine M. L.^ORCID

Abstract

AbstractEffective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.

Publisher

Springer Science and Business Media LLC

Subject

Computer Science Applications,History,Education

Link

http://www.nature.com/articles/s41698-021-00168-1.pdf

Reference51 articles.

1. Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356–387 (2018).

2. Sawyers, C. L. The cancer biomarker problem. Nature 452, 548–552 (2008).

3. Letai, A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med. 23, 1028–1035 (2017).

4. Meric-Bernstam, F. et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. JCO 33, 2753–2762 (2015).

5. van der Velden, D. L. et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature 574, 127–131 (2019).

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations;Cancers;2024-01-29

2. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold;Molecular Cancer;2024-01-10

3. Systems approach for congruence and selection of cancer models towards precision medicine;PLOS Computational Biology;2024-01-10

4. Computational precision therapeutics and drug repositioning;Comprehensive Precision Medicine;2024

5. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response;2023-12-28